Skip to main content
TipRanks
Go Ultimate75% OFF

LBT Innovations Limited (CC5) AI Stock Analysis

9 Followers
AU:CC5

LBT Innovations Limited

(ASX:CC5)

Select Model
Rating:40Underperform
Price Target:AUD 0.02â–¼(-5.88% Downside)
Action:downgraded
Date:11/13/26

The score is held down primarily by weak financial performance (FY2026 margin collapse, return to losses, and negative operating/free cash flow), alongside very poor technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.

Positive Factors
Moderate LeverageDebt at roughly 0.4x equity in FY2026, similar to FY2025, indicates current leverage is moderate rather than excessive. This gives the company more balance-sheet flexibility than a heavily debt-funded model, although profitability still needs to recover.
Negative Factors
Revenue and Margin ContractionThe FY2026 combination of roughly 10.7% revenue decline and negative gross profit indicates weakening demand or monetization alongside costs exceeding sales. This damages operating leverage and makes a durable recovery harder until revenue and unit economics improve together.

LBT Innovations Limited (CC5) vs. iShares MSCI Australia ETF (EWA)

-60%-40%-20%0%20%40%AU:CC5-43.33%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 35.92M
Dividend Yield
―
Average Volume (3M)
888.39K
Price to Earnings (P/E)
-16.9
Beta (1Y)
1.05
Revenue Growth
-15.42%
EPS Growth
-210.00%
Country
Australia
Employees
26
Sector
Technology
Sector Strength
61
Industry
Software - Infrastructure

LBT Innovations Limited Business Overview & Revenue Model

Company Description

Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving m...

LBT Innovations Limited Financial Statement Overview

Summary

Overall fundamentals are weak, driven by a sharp FY2026 profitability breakdown (revenue down ~10.7% and gross profit turning negative), a return to net losses after FY2025 profit, and heavy cash burn with negative operating and free cash flow. The balance sheet is only moderately levered (~0.4x debt-to-equity in FY2026), but past equity stress (negative equity in FY2023) and lack of consistent earnings/cash generation reduce financial quality and visibility.

Income Statement

28Negative

Balance Sheet

55Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue7.48M4.62M5.46M1.26M2.13M2.13M
Gross Profit1.52M-1.98M3.96M1.11M1.71M1.33M
EBITDA-3.87M-3.73M220.00K-4.05M-17.12M-5.72M
Net Income-1.86M-2.24M1.68M-3.74M-22.52M-6.64M
Balance Sheet
Total Assets13.55M13.55M10.77M7.93M7.37M31.52M
Cash, Cash Equivalents and Short-Term Investments1.70M1.70M1.26M2.35M2.02M2.79M
Total Debt2.98M2.98M2.21M3.19M3.39M4.29M
Total Liabilities6.02M6.02M5.12M5.51M7.47M10.19M
Stockholders Equity7.52M7.52M5.64M2.42M-105.00K21.34M
Cash Flow
Free Cash Flow-260.50K-2.58M1.13M-3.68M-1.40M-5.00M
Operating Cash Flow-234.00K-2.57M1.16M-3.67M-1.40M-4.95M
Investing Cash Flow-1.91M-475.00K-2.33M-6,000-305.00K-1.24M
Financing Cash Flow3.77M3.48M83.00K4.01M935.00K-637.00K

LBT Innovations Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.02

Price Trends

50DMA0.02Positive
100DMA0.02Positive
200DMA0.02Negative

Market Momentum

MACD-0.00Negative
RSI51.93Neutral
STOCH146.67Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CC5, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 51.93 is Neutral, neither overbought nor oversold. The STOCH value of 146.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CC5.

LBT Innovations Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

AU:CC5 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
AU:SENAU:SEN55NeutralAUD 35.48M81.081.06%15.80%4.73%―
AU:QFEAU:QFE52NeutralAUD 30.52M0.76265.43%105.24%-24.21%―
AU:CYBAU:CYB43NeutralAUD 13.04M-1.69-162.05%―-11.66%89.02%
AU:TALAU:TAL41NeutralAUD 18.96M-10.00-26.53%―-42.68%32.10%
AU:PILAU:PIL40UnderperformAUD 10.04M-10.00147.62%―-29.96%-12.50%
AU:CC5AU:CC540UnderperformAUD 38.16M-16.90-43.22%―-15.42%-210.00%

* Technology Sector Average

Performance Comparison

-50%-25%0%25%50%AU:CC5AU:SENAU:QFEAU:PILAU:CYBAU:TALDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:CC5 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:CC5LBT Innovations Limited0.02-0.01-43.33%
AU:SENSenetas Corporation Limited2.10-0.43-17.13%
AU:QFEQuickFee Ltd.0.070.0247.06%
AU:PILPeppermint Innovation Limited0.010.000.00%
AU:CYBSovereign Cloud Holdings Ltd.0.06-0.02-21.62%
AU:TALHSC Technology Group Ltd.0.06-0.03-31.25%

LBT Innovations Limited Corporate Events

Clever Culture Systems Provides Managing Director’s Presentation at 2026 AGM

Nov 17, 2026

Clever Culture Systems develops intelligent automation solutions for microbiology laboratories, including APAS Independence, which uses artificial intelligence and machine learning to automate culture-plate imaging, analysis and interpretation. The s...

Clever Culture Systems Reports APAS Customer Growth and Market Expansion

Nov 17, 2026

Clever Culture Systems supplies APAS automated culture-plate reading technology for pharmaceutical environmental monitoring and clinical laboratories. In FY26, it doubled its global pharmaceutical customer base, placed 11 APAS Independence instrument...

Clever Culture Systems Applies to Quote 62.5 Million Securities

Nov 9, 2026

The release identifies Clever Culture Systems Limited but provides no information on its industry, products, services or market focus. The company applied for quotation of 62,500,000 fully paid ordinary securities under ASX code CC5, with an issue da...

Clever Culture Proposes Issue of Shares and Options

Nov 2, 2026

Clever Culture Systems Limited announced a proposed issue of up to 62.5 million fully paid ordinary shares, along with 91.3 million options expiring on 30 November 2029 with a $0.03 exercise price. The securities are scheduled for issue on 9 November...

CCS raises $2.6 million to expand APAS automation

Nov 2, 2026

Clever Culture Systems develops AI-enabled microbiology automation for pharmaceutical manufacturers through its APAS® environmental monitoring platform. The company’s portfolio includes APAS® Independence and the planned smaller-format APAS® Revoluti...

Clever Culture Systems Updates Share Registry Address for Investors

Oct 29, 2026

Clever Culture Systems Ltd, an Adelaide-based specialist in AI-driven microbiology automation, develops and markets the APAS Independence system, which automates culture plate reading for pharmaceutical manufacturing and clinical laboratories and hol...

CCS Taps PSC Biotech to Boost APAS Independence Pharma Sales Reach

Oct 13, 2026

Clever Culture Systems has appointed PSC Biotech as sole sales agent for its APAS Independence system across pharmaceutical manufacturing markets in the United States, Canada and Singapore. The deal opens access to a wider base of regional, medium an...

Clever Culture Systems Plans Equity Placement to Fund Growth

Oct 13, 2026

Clever Culture Systems Limited has notified the ASX of a proposed placement of up to 2,820,513 ordinary fully paid shares under its Appendix 3B lodgement. The new securities, to be issued on 20 November 2026, signal the company’s intention to raise a...

Clever Culture Systems Plans New ASX-Listed Option Issue

Oct 13, 2026

Clever Culture Systems Limited has notified the ASX of a proposed issue of new options as part of a placement or similar capital-raising transaction. The company has lodged an Appendix 3B outlining its plan for the exchange to quote these securities,...

Clever Culture Systems Aligns Board and Staff Incentives Ahead of 2026 AGM

Oct 13, 2026

Clever Culture Systems Limited has called shareholders to its 2026 Annual General Meeting, to be held in person at its Adelaide offices on 17 November, with remote observation available via a non-participatory Zoom webinar. The company is moving furt...

Clever Culture Systems Wins Expanded Novo Nordisk Order as APAS Nears Global Validation

Sep 7, 2026

Clever Culture Systems Ltd, an Adelaide-based specialist in AI microbiology automation, has secured a new purchase order from Novo Nordisk for two additional APAS® Independence instruments, lifting the pharma group’s installed base to three. The inst...

Clever Culture Systems Files Appendix 4G, Confirms Governance Compliance

Aug 31, 2026

Clever Culture Systems Ltd has lodged its Appendix 4G and confirmed that its corporate governance statement for the year to 30 June 2026 is available on its website, as required under ASX listing rules. The statement, current as at 31 August 2026 and...

Clever Culture Systems Tightens Governance and Diversity Framework

Aug 31, 2026

Clever Culture Systems has outlined its adherence to the ASX Corporate Governance Council’s fourth‑edition principles, detailing board responsibilities, delegation to the CEO and key decisions reserved for directors, as well as processes for appointi...

Clever Culture Systems expands global footprint for FDA-cleared AI lab platform

Aug 31, 2026

Clever Culture Systems has positioned its APAS Independence platform as a best-in-class, AI-driven tool for automated culture plate reading in microbiology, and it is currently the only artificial intelligence technology cleared by the U.S. FDA for t...

Clever Culture Systems Swings to Loss as Revenue Falls and Costs Rise

Aug 31, 2026

Clever Culture Systems reported a sharp deterioration in its 2026 financial performance, with revenue falling 29.6% to $4.67 million and the group swinging from a prior-year profit to a $2.24 million net loss. The decline was driven by lower income,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026